RecruitingNot ApplicableNCT06315192

Stroke Alarm Efficacy Trial


Sponsor

Region Skane

Enrollment

500 participants

Start Date

Sep 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset. This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population. A total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size. Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study. Patients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by: 1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR 2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR 3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR 4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard. A control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a/5b 1-4), presence of neglect/inattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (Stroke Alarm Efficacy Trial) is testing a smartphone app designed to detect stroke symptoms early and alert emergency services, in people who are at high risk of having a stroke. Researchers want to see if this technology can reduce the time between stroke onset and hospital treatment. **You may be eligible if...** - You are 50 years or older - You have mild-to-no prior disability (modified Rankin scale score 0–2) - You have been recently diagnosed with one of the following: a TIA (mini-stroke) with high-risk features, an ischemic stroke with atrial fibrillation or large artery disease, atrial fibrillation with a high stroke risk score (CHA2DS2-VASc ≥4) and not fully anticoagulated, or a recent brain bleed with atrial fibrillation - You have been using a smartphone for at least 1 year **You may NOT be eligible if...** - You are under 50 years of age - You have significant disability from a prior stroke - You do not use a smartphone or have been using one for less than a year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEStroke Alarm

Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.


Locations(10)

Sahlgrenska University Hospital

Gothenburg, Sweden

Hässleholms sjukhus

Hässleholm, Sweden

Helsingborg lasarett

Helsingborg, Sweden

Karolinska University Hospital Huddinge

Huddinge, Sweden

Linköping university hospital

Linköping, Sweden

Skane University hospital

Lund, Sweden

Skåne University Hospital Malmö

Malmö, Sweden

Karolinska Sjukhuset

Stockholm, Sweden

Södersjukhuset

Stockholm, Sweden

Uppsala University hospital

Uppsala, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06315192


Related Trials